Trogenix募集了95M美元,用于发展侵略性癌症的基因疗法,从2026年开始首次进行人类试验。 Trogenix raised $95M to develop gene therapies for aggressive cancers, with first human trials starting in 2026.

爱丁堡大学的衍生公司 Trogenix 已筹集 9500 万美元的 A 轮融资，以推进其针对胶质母细胞瘤和结直肠肝转移等侵袭性实体瘤的精准癌症疗法。 Trogenix, a University of Edinburgh spinout, has raised $95 million in Series A funding to advance its precision cancer therapies for aggressive solid tumors like glioblastoma and colorectal liver metastases. 在IQ Capital的领导下,并得到Eli Lilly、癌症研究地平线和国家脑肿瘤学会等投资者的支持,基金将支持其Odysseusí平台的临床开发,该平台利用工程基因疗法同时杀死癌症细胞,刺激长期免疫反应。 Led by IQ Capital and backed by investors including Eli Lilly, Cancer Research Horizons, and the National Brain Tumor Society, the funds will support clinical development of its Odysseus® platform, which uses engineered gene therapies to simultaneously kill cancer cells and stimulate long-term immune responses. 预计2026年初将首次服用血浆瘤的病人剂量,计划扩大至肝癌和肺癌。 First patient dosing in glioblastoma is expected in early 2026, with plans to expand into liver and lung cancers. 投资标志着癌症研究地平线迄今为止最大的投资,并反映出对该公司提供一次性高危癌症治疗的潜力的强烈信心。 The investment marks Cancer Research Horizons’ largest to date and reflects strong confidence in the company’s potential to deliver one-time, curative treatments for high-risk cancers.